{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:26:18Z","timestamp":1781843178226,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01DA046910-02S3"],"award-info":[{"award-number":["U01DA046910-02S3"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pharmacy administration and dispensing of methadone treatment for opioid use disorder (PADMOUD) may address inadequate capability of opioid treatment programs (OTPs) in the US by expanding access to methadone at community pharmacies nationally. PADMOUD is vastly underutilized in the US. There is no published US study on OUD patients\u2019 perspectives on PADMOUD. Data are timely and needed to inform the implementation of PADMOUD in the US to address its serious opioid overdose crisis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patient participants of the first completed US trial on PADMOUD through electronic prescribing for methadone (parent study) were interviewed to explore implementation-related factors for PADMOUD. All 20 participants of the parent study were invited to participate in this interview study. Each interview was recorded and transcribed verbatim. Thematic analysis was conducted to identify emergent themes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen participants completed the interview. Patients\u2019 perspectives on PADMOUD were grouped into five areas. Participants reported feasibility of taking the tablet formulation of methadone at the pharmacy and identified benefits from PADMOUD (e.g., better access, efficiency, convenience) compared with usual care at the OTP. Participants perceived support for PADMOUD from their family\/friends, OTP staff, and pharmacy staff. PADMOUD was perceived to be a great option for stable patients with take-home doses and those with transportation barriers. The distance (convenience), office hours, and the cost were considered factors most influencing their decision to receive methadone from a pharmacy. Nonjudgmental communication, pharmacists\u2019 training on methadone treatment, selection of patients (stable status), workflow of PADMOUD, and protection of privacy were considered key factors for improving operations of PADMOUD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study presents the first findings on patient perspectives on PADMOUD. Participants considered pharmacies more accessible than OTPs, which could encourage more people to receive methadone treatment earlier and help transition stable patients from an OTP into a local pharmacy. The findings have timely implications for informing implementation strategies of PADMOUD that consider patients\u2019 views and needs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00399-6","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T15:06:07Z","timestamp":1690988767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S."],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-2259","authenticated-orcid":false,"given":"Li-Tzy","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"399_CR1","volume-title":"Drug overdose deaths in the United States 1999\u20132016 NCHS Data Brief 294","author":"H Hedegaard","year":"2017","unstructured":"Hedegaard H, Warner M, Mini\u00f1o AM. Drug overdose deaths in the United States 1999\u20132016 NCHS Data Brief 294. Hyattsville: National Center for Health Statistics; 2017."},{"issue":"8","key":"399_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.sapharm.2017.12.009","volume":"15","author":"WM Compton","year":"2019","unstructured":"Compton WM, Jones CM, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the US opioid crisis. Res Social Adm Pharm. 2019;15(8):910\u20136.","journal-title":"Res Social Adm Pharm"},{"key":"399_CR3","volume-title":"Drug overdose deaths in the United States 1999\u20132020 NCHS data brief 428","author":"H Hedegaard","year":"2021","unstructured":"Hedegaard H, Mini\u00f1o AM, Spencer MR, Warner M. Drug overdose deaths in the United States 1999\u20132020 NCHS data brief 428. Hyattsville: National Center for Health Statistics. Hyattsville; 2021."},{"key":"399_CR4","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. 2022. Provisional drug overdose death counts. National Center for Health Statistics. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"issue":"11","key":"399_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/jama.2016.10542","volume":"316","author":"BD Stein","year":"2016","unstructured":"Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211\u20132.","journal-title":"JAMA"},{"issue":"8","key":"399_CR6","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55-63.","journal-title":"Am J Public Health"},{"issue":"22","key":"399_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2014tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136.","journal-title":"N Engl J Med"},{"key":"399_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","volume":"169","author":"LT Wu","year":"2016","unstructured":"Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117\u201327. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.10.015.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"399_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1186\/s12889-018-5982-8","volume":"18","author":"H Zhu","year":"2018","unstructured":"Zhu H, Wu LT. National trends and characteristics of inpatient detoxification for drug use disorders in the United States. BMC Public Health. 2018;18(1):1073.","journal-title":"BMC Public Health"},{"key":"399_CR10","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). 2023. Medication-assisted treatment (MAT) statutes regulations and guidelines. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines."},{"issue":"1","key":"399_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.12307","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108\u201312.","journal-title":"J Rural Health"},{"issue":"5","key":"399_CR12","first-page":"347","volume":"67","author":"H Joseph","year":"2000","unstructured":"Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT). Mount Sinai J Med. 2000;67(5):347.","journal-title":"Mount Sinai J Med"},{"key":"399_CR13","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for opioid use disorder treatment improvement protocol (TIP) series 63 full document HHS Publication No Publication No PEP20\u201302\u201301\u2013006 First released 2018. Revised 2019 and 2020. Rockville, substance abuse and mental health services administration. 2020."},{"key":"399_CR14","volume-title":"federal guidelines for opioid treatment programs no (SMA) PEP15-FEDGUIDEOTP Rockville substance abuse and mental health services administration","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2015","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). federal guidelines for opioid treatment programs no (SMA) PEP15-FEDGUIDEOTP Rockville substance abuse and mental health services administration. Rockvill: HHS Publication; 2015."},{"issue":"8","key":"399_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183172","volume":"12","author":"DM Qato","year":"2017","unstructured":"Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007\u20132015. PLoS ONE. 2017;12(8): e0183172.","journal-title":"PLoS ONE"},{"key":"399_CR16","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), 2022b. Opioid Treatment Program Directory. https:\/\/dpt2.samhsa.gov\/treatment\/directory.aspx."},{"key":"399_CR17","unstructured":"Code of Federal Regulations (CFR). PART 8\u2014medication assisted treatment for opioid use disorders. https:\/\/www.ecfr.gov\/current\/title-42\/chapter-I\/subchapter-A\/part-8."},{"key":"399_CR18","unstructured":"Australian Institute of Health and Welfare (AIHW), 2018. National opioid pharmacotherapy statistics (NOPSAD) 2017. https:\/\/www.aihw.gov.au\/reports\/alcohol-other-drug-treatment-services\/nopsad-2017\/contents\/summary."},{"issue":"11","key":"399_CR19","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1111\/j.1360-0443.2007.02016.x","volume":"102","author":"J Sheridan","year":"2007","unstructured":"Sheridan J, Manning V, Ridge G, Mayet S, Strang J. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995\u20132005. Addiction. 2007;102(11):1824\u201330.","journal-title":"Addiction"},{"issue":"4","key":"399_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/dar.12032","volume":"32","author":"BB Chaar","year":"2013","unstructured":"Chaar BB, Wang H, Day CA, Hanrahan JR, Winstock AR, Fois R. Factors influencing pharmacy services in opioid substitution treatment. Drug Alcohol Rev. 2013;32(4):426\u201334.","journal-title":"Drug Alcohol Rev"},{"issue":"9","key":"399_CR21","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/j.1360-0443.1991.tb01883.x","volume":"86","author":"M Gossop","year":"1991","unstructured":"Gossop M, Grant M. A six country survey of the content and structure of heroin treatment programmes using methadone. Br J Addict. 1991;86(9):1151\u201360.","journal-title":"Br J Addict"},{"issue":"6","key":"399_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/09687630600790153","volume":"13","author":"R McCormick","year":"2006","unstructured":"McCormick R, Bryant L, Sheridan J, Gonzalez J. New Zealand community pharmacist attitudes toward opioid-dependent clients. Drugs Edu Prev Policy. 2006;13(6):563\u201375.","journal-title":"Drugs Edu Prev Policy"},{"issue":"2","key":"399_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1360-0443.2009.02774.x","volume":"105","author":"AR Winstock","year":"2010","unstructured":"Winstock AR, Lea T, Sheridan J. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria. Aust Addict. 2010;105(2):335\u201342.","journal-title":"Aust Addict"},{"issue":"6","key":"399_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/ADM.0000000000000156","volume":"9","author":"JK Eibl","year":"2015","unstructured":"Eibl JK, Gomes T, Martins D, Camacho X, Juurlink DN, Mamdani MM, Dhalla IA, Marsh DC. Evaluating the effectiveness of first-time methadone maintenance therapy across northern, rural, and urban regions of Ontario, Canada. J Addict Med. 2015;9(6):440.","journal-title":"J Addict Med"},{"key":"399_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/0706743717711167","volume":"62","author":"JK Eibl","year":"2017","unstructured":"Eibl JK, Morin K, Leinonen E, Marsh DC. The state of opioid agonist therapy in Canada 20 years after federal oversight. Can J Psychiatry. 2017;62:444\u201350.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"399_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.japh.2019.10.014","volume":"60","author":"AJ Luli","year":"2020","unstructured":"Luli AJ, Bounthavong M, Watanabe JH. Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. J Am Pharm Assoc. 2020;60(2):297\u2013303.","journal-title":"J Am Pharm Assoc"},{"key":"399_CR27","unstructured":"SAMHSA. Certification of opioid treatment programs. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/become-accredited-opioid-treatment-program."},{"key":"399_CR28","unstructured":"Pew charitable trusts overview of opioid treatment program regulations by state. Sept 19, 2022. https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/issue-briefs\/2022\/09\/overview-of-opioid-treatment-program-regulations-by-state."},{"key":"399_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adaw.32583","volume":"32","author":"G Enos","year":"2020","unstructured":"Enos G. Report: It\u2019s time for insurers to ramp up methadone coverage in 2020. Alcohol Drug Abuse Weekly. 2020;32:1\u20138. https:\/\/doi.org\/10.1002\/adaw.32583.","journal-title":"Alcohol Drug Abuse Weekly"},{"key":"399_CR30","unstructured":"Ohio.gov. Rule 5122\u201340\u201315 | Medication units. 2019. https:\/\/codes.ohio.gov\/ohio-administrative-code\/rule-5122-40-15."},{"key":"399_CR31","unstructured":"FDA, 2018. The voice of the patient: opioid use disorder. https:\/\/www.fda.gov\/media\/124391\/download."},{"issue":"6","key":"399_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/2374373520948401","volume":"7","author":"J Schlaudecker","year":"2020","unstructured":"Schlaudecker J, Zamudio O, Goodnow K, Pallerla H, Regan S. Using patient voice to personalize the opioid epidemic: an evaluation of 2 educational interventions. J Patient Exp. 2020;7(6):964\u20138.","journal-title":"J Patient Exp"},{"key":"399_CR33","unstructured":"Centers for medicare and medicaid services (CMS). 2022. E-Prescribing. https:\/\/www.cms.gov\/Medicare\/E-Health\/Eprescribing#:~:text=Electronic%20prescribing%20for%20controlled%20substances%20(EPCS)%20is%20the%20process%20of,Enforcement%20Administration%20(DEA)%20requirements."},{"issue":"2","key":"399_CR34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/add.15641","volume":"117","author":"LT Wu","year":"2022","unstructured":"Wu LT, John WS, Morse ED, Adkins S, Pippin J, Brooner RK, Schwartz RP. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Addiction. 2022;117(2):444\u201356. https:\/\/doi.org\/10.1111\/add.15641.","journal-title":"Addiction"},{"issue":"11","key":"399_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ptdy.2018.10.021","volume":"24","author":"L Haberkorn","year":"2018","unstructured":"Haberkorn L. Easy to reach and ready to help: not just dispensing medication. Pharmacy Today. 2018;24(11):38\u20139.","journal-title":"Pharmacy Today"},{"key":"399_CR36","unstructured":"National Association of Chain Drug Stores (NACDS), 2013. NACDS impact report. community pharmacy fills gaps in access and affordability for patients, payers. March. 2013, page 1\u20135."},{"key":"399_CR37","unstructured":"Providers clinical support system. https:\/\/pcssnow.org\/"},{"key":"399_CR38","unstructured":"Governor\u2019s Institute. http:\/\/addictionmedicineupdates.org\/wp-content\/uploads\/2017\/10\/Final-Methadone-and-Buprenorphine-Take-Home-Guidelines.pdf."},{"key":"399_CR39","unstructured":"SAMHSA. Methadone take-home flexibilities extension guidance. 2023. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance."},{"issue":"1","key":"399_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","volume":"14","author":"K Marchand","year":"2019","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, Schechter MT, Oviedo-Joekes E. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"3","key":"399_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10389-016-0714-y","volume":"24","author":"A Laird","year":"2016","unstructured":"Laird A, Hunter C, Sardar CM, Fitzgerald NM, Lowrie R. Community pharmacy-based opiate substitution treatment and related health services: a study of 508 patients and 111 pharmacies. J Public Health. 2016;24(3):193\u2013207.","journal-title":"J Public Health"},{"issue":"4","key":"399_CR42","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/pubmed\/fdw138","volume":"39","author":"A Radley","year":"2017","unstructured":"Radley A, Melville K, Easton P, Williams B, Dillon JF. \u2018Standing outside the junkie door\u2019\u2014service users\u2019 experiences of using community pharmacies to access treatment for opioid dependency. J Public Health. 2017;39(4):846\u201355.","journal-title":"J Public Health"},{"issue":"6","key":"399_CR43","first-page":"639","volume":"32","author":"HD Robertson","year":"2015","unstructured":"Robertson HD, Bond C, Matheson C. The evolution of pharmaceutical care for drug misusers. Fam Pract. 2015;32(6):639\u201345.","journal-title":"Fam Pract"},{"issue":"4","key":"399_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/08897077.2019.1640833","volume":"40","author":"B Allen","year":"2019","unstructured":"Allen B, Nolan ML, Paone D. Underutilization of medications to treat opioid use disorder: What role does stigma play? Subst Abus. 2019;40(4):459\u201365.","journal-title":"Subst Abus"},{"issue":"2","key":"399_CR45","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/0049124118799377","volume":"50","author":"NM Deterding","year":"2021","unstructured":"Deterding NM, Waters MC. Flexible coding of in-depth interviews: a twenty-first-century approach. Sociol Methods Res. 2021;50(2):708\u201339.","journal-title":"Sociol Methods Res"},{"issue":"1","key":"399_CR46","first-page":"14","volume":"3","author":"L Wong","year":"2008","unstructured":"Wong L. Data analysis in qualitative research: a brief guide to using nvivo. Malays Fam Phys. 2008;3(1):14\u201320.","journal-title":"Malays Fam Phys"},{"issue":"4","key":"399_CR47","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.sapharm.2018.06.006","volume":"15","author":"KA Look","year":"2019","unstructured":"Look KA, Kile M, Morgan K, Roberts A. Community pharmacies as access points for addiction treatment. Res Social Adm Pharm. 2019;15(4):404\u20139.","journal-title":"Res Social Adm Pharm"},{"issue":"11","key":"399_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamapsychiatry.2020.1624","volume":"77","author":"RA Kleinman","year":"2020","unstructured":"Kleinman RA. Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiat. 2020;77(11):1\u20139.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"399_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","volume":"46","author":"JJ Lister","year":"2020","unstructured":"Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273\u201388.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"399_CR50","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","volume":"71","author":"SC Sigmon","year":"2014","unstructured":"Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiat. 2014;71(4):359\u201360.","journal-title":"JAMA Psychiat"},{"issue":"93","key":"399_CR51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","volume":"1","author":"S Amiri","year":"2018","unstructured":"Amiri S, Lutz R, Soc\u00edas ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;1(93):26\u201330.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"399_CR52","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s11606-018-4801-3","volume":"34","author":"SL Calcaterra","year":"2019","unstructured":"Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039\u201342.","journal-title":"J Gen Intern Med"},{"issue":"341","key":"399_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4851","volume":"16","author":"J Strang","year":"2010","unstructured":"Strang J, Hall W, Hickman M, Bird SM. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993\u20132008): analyses using OD4 index in England and Scotland. BMJ. 2010;16(341): c4851.","journal-title":"BMJ"},{"issue":"3","key":"399_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0955-3959(00)00047-5","volume":"11","author":"L Luger","year":"2000","unstructured":"Luger L, Bathia N, Alcorn R, Power R. Involvement of community pharmacists in the care of drug misusers: pharmacy-based supervision of methadone consumption. Int J Drug Policy. 2000;11(3):227\u201334.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"399_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/09595230701710852","volume":"27","author":"P Lawrinson","year":"2008","unstructured":"Lawrinson P, Roche A, Terao H. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. Drug Alcohol Rev. 2008;27(1):47\u201353.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"399_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-022-00323-4","volume":"17","author":"N Day","year":"2022","unstructured":"Day N, Wass M, Smith K. Virtual opioid agonist treatment: Alberta\u2019s virtual opioid dependency program and outcomes. Addict Sci Clin Pract. 2022;17(1):1\u20133.","journal-title":"Addict Sci Clin Pract"},{"key":"399_CR57","first-page":"12","volume":"1","author":"ME Keller","year":"2015","unstructured":"Keller ME, Kelling SE, Cornelius DC, Oni HA, Bright DR. Enhancing practice efficiency and patient care by sharing electronic health records. Perspect Health Inf Manag. 2015;1:12.","journal-title":"Perspect Health Inf Manag"},{"issue":"11","key":"399_CR58","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1046\/j.1360-0443.2002.00241.x","volume":"97","author":"C Matheson","year":"2002","unstructured":"Matheson C, Bond CM, Pitcairn J. Community pharmacy services for drug misusers in Scotland: what difference does 5 years make? Addiction. 2002;97(11):1405\u201311.","journal-title":"Addiction"},{"issue":"8","key":"399_CR59","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.sapharm.2019.02.003","volume":"15","author":"PP Le","year":"2019","unstructured":"Le PP, Braunack-Mayer A. Perspectives on privacy in the pharmacy: The views of opioid substitution treatment clients. Res Social Adm Pharm. 2019;15(8):1021\u20136.","journal-title":"Res Social Adm Pharm"},{"key":"399_CR60","unstructured":"Centers for Disease Control and Prevention (CDC). Advancing team-based care through collaborative practice agreements: a resource and implementation guide for adding pharmacists to the care team. Atlanta GA USA centers for disease control and prevention US Department of Health and Human Services. 2017"},{"key":"399_CR61","volume-title":"Mixed methods integrating quantitative and qualitative data collection and analysis while studying patient-centered medical home models agency for healthcare research and quality","author":"J Wisdom","year":"2013","unstructured":"Wisdom J, Creswell JW. Mixed methods integrating quantitative and qualitative data collection and analysis while studying patient-centered medical home models agency for healthcare research and quality. Rockville: AHRQ Publication; 2013."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00399-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00399-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00399-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T16:05:16Z","timestamp":1690992316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00399-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00399-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This interview study was approved by the Duke University Health System Institutional Review Board. The parent study\u2019s ClinicalTrials.gov Identifier is NCT04308694.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Mannelli has consulted for Alkermes, Intracellular Therapies, Indivior, and Guidepoint Global. Dr. Schwartz has consulted for Verily Life Sciences. He was Principal Investigator of a NIDA-funded study that has received medication at no cost to the study from Alkermes and Indivior. The other authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}